Paper Details

Paper Title

Eligibility for Low-Dose Rivaroxaban Based on the COMPASS Trial: Insights from the Veterans Affairs Healthcare System.

Paper Journal Title

Cardiovasc Drugs Ther

Paper Citation Count

Paper Publication Year

2021

Bio Mention

ASCVD, Rivaroxaban, atherosclerotic vascular disease, diabetes, hypertension, patients, rivaroxaban

Mesh Descriptor

Author Name	Affiliation
Dhruv Mahtta	Michael E. DeBakey Veterans Affairs Medical Center Health Services Research & Development Center for Innovations
Julia M Akeroyd	Michael E. DeBakey Veterans Affairs Medical Center Health Services Research & Development Center for Innovations
John A Spertus	Saint Luke's Mid America Heart Institute
John A Spertus	University of Missouri-Kansas City
John A Spertus	Saint Luke's Mid America Heart Institute
John A Spertus	University of Missouri-Kansas City
Deepak L Bhatt	Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School
Laura A Petersen	Baylor College of Medicine
Christie M Ballantyne	Baylor College of Medicine
Christie M Ballantyne	Michael E. DeBakey Veterans Affairs Medical Center
Christie M Ballantyne	Baylor College of Medicine
Christie M Ballantyne	Michael E. DeBakey Veterans Affairs Medical Center
Salim S Virani	Health Services Research and Development (152), Michael E. DeBakey Veterans Affairs Medical Center
Salim S Virani	Michael E. DeBakey Veterans Affairs Medical Center Health Services Research & Development Center for Innovations
Salim S Virani	Baylor College of Medicine
Salim S Virani	Michael E. DeBakey Veterans Affairs Medical Center

Column Actions